Search

Your search keyword '"Orfanidis, Ioannis"' showing total 17 results
Start Over Author "Orfanidis, Ioannis"
17 results on '"Orfanidis, Ioannis"'

1. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Author

Dimopoulos, Meletios A, Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Kampfenkel, Tobias, Liu, Weiping, Wang, Jianping, Kosh, Michele, Tran, NamPhuong, Carson, Robin, and Sonneveld, Pieter

Published
2023
Full Text
View/download PDF

2. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Author

Alegre Amor, Adrian, Baldini, Luca, Beksac, Meral, Belotti, Angelo, Benboubker, Lotfi, Besemer, Britta, Besisik, Sevgi, Bila, Jelena, Boccadoro, Mario, Cavo, Michele, De La Rubia Comos, Javier, Delimpasi, Sosana, Dimopoulos, Meletios A., Doyen, Chantal, Dytfeld, Dominik, Engelhardt, Monika, Facon, Thierry, Foà, Roberto, Goldschmidt, Hartmut, Grosicki, Sebastian, Hajek, Roman, Hayri Ozsan, Guner, Hulin, Cyrille, Iversen, Brian, Karlin, Lionel, Katodritou, Eirini, Knop, Stefan, Kyrtsonis, Marie-Christine, Lahuerta, Juan Jose, Leleu, Xavier, Martinez Chamorro, Carmen, Mateos Manteca, María-Victoria, Meuleman, Nathalie, Minnema, Monique, Moreau, Philippe, Offidani, Massino, Oriol Rocafiguera, Albert, Pehlivan, Mustafa, Pour, Ludek, Roerdink, Henk Th.J., Rosinol Dacsh, Laura, Salwender, Hans, Sonneveld, Pieter, Symeonidis, Anargyros, Toftmann Hansen, Charlotte, Tuglular, Tulin, Unal, Ali, Vlummens, Philip, Vural, Filiz, Wu, Ka Lung, Zweegman, Sonja, Dimopoulos, Meletios A, Terpos, Evangelos, Symeonidis, Argiris, Oriol, Albert, Mateos, Maria-Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M, Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, and Carson, Robin

Published
2021
Full Text
View/download PDF

3. Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Author

Dimopoulos, Meletios A., primary, Terpos, Evangelos, additional, Boccadoro, Mario, additional, Delimpasi, Sosana, additional, Beksac, Meral, additional, Katodritou, Eirini, additional, Moreau, Philippe, additional, Baldini, Luca, additional, Symeonidis, Argiris, additional, Bila, Jelena, additional, Oriol, Albert, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Orfanidis, Ioannis, additional, Kampfenkel, Tobias, additional, Liu, Weiping, additional, Kosh, Michele, additional, Tran, NamPhuong, additional, Carson, Robin, additional, and Sonneveld, Pieter, additional

Published
2022
Full Text
View/download PDF

5. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

Author

Janssen Research and Development, Terpos, Evangelos, Dimopoulos, Meletios A., Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Pompa, Alessandra, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria Victoria, Einsele, Hermann, Orfanidis, Ioannis, Gries, Katharine S., Fastenau, John, Liu, Kevin, He, Jianming, Kampfenkel, Tobias, Qiu, Yanping, Amin, Himal, Carson, Robin, Sonneveld, Pieter, Janssen Research and Development, Terpos, Evangelos, Dimopoulos, Meletios A., Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Pompa, Alessandra, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria Victoria, Einsele, Hermann, Orfanidis, Ioannis, Gries, Katharine S., Fastenau, John, Liu, Kevin, He, Jianming, Kampfenkel, Tobias, Qiu, Yanping, Amin, Himal, Carson, Robin, and Sonneveld, Pieter

Abstract

In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received ≥1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients' health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.

Published
2022

6. Supplementary files of the article Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial [Dataset]

Author

Terpos, Evangelos, Dimopoulos, Meletios A., Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Pompa, Alessandra, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria Victoria, Einsele, Hermann, Orfanidis, Ioannis, Gries, Katharine S., Fastenau, John, Liu, Kevin, He, Jianming, Kampfenkel, Tobias, Qiu, Yanping, Amin, Himal, Carson, Robin, Sonneveld, Pieter, Terpos, Evangelos, Dimopoulos, Meletios A., Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Pompa, Alessandra, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria Victoria, Einsele, Hermann, Orfanidis, Ioannis, Gries, Katharine S., Fastenau, John, Liu, Kevin, He, Jianming, Kampfenkel, Tobias, Qiu, Yanping, Amin, Himal, Carson, Robin, and Sonneveld, Pieter

Published
2022

8. Supplementary methods from Effects of altered cellular ultrastructure on energy metabolism in diabetic cardiomyopathy: an in silico study

Author

Ghosh, Shouryadipta, Guglielmi, Giovanni, Orfanidis, Ioannis, Spill, Fabian, Hickey, Anthony, Hanssen, Eric, and Rajagopal, Vijay

Abstract

Diabetic cardiomyopathy is a leading cause of heart failure in diabetes. At the cellular level, diabetic cardiomyopathy leads to altered mitochondrial energy metabolism and cardiomyocyte ultrastructure. We combined electron microscopy (EM) and computational modelling to understand the impact of diabetes-induced ultrastructural changes on cardiac bioenergetics. We collected transverse micrographs of multiple control and type I diabetic rat cardiomyocytes using EM. Micrographs were converted to finite-element meshes, and bioenergetics was simulated over them using a biophysical model. The simulations also incorporated depressed mitochondrial capacity for oxidative phosphorylation (OXPHOS) and creatine kinase (CK) reactions to simulate diabetes-induced mitochondrial dysfunction. Analysis of micrographs revealed a 14% decline in mitochondrial area fraction in diabetic cardiomyocytes, and an irregular arrangement of mitochondria and myofibrils. Simulations predicted that this irregular arrangement, coupled with the depressed activity of mitochondrial CK enzymes, leads to large spatial variation in ADP/ATP profile of diabetic cardiomyocytes. However, when spatially averaged, myofibrillar ADP/ATP ratios of a cardiomyocyte do not change with diabetes. Instead, average concentration of inorganic phosphate rises by 40% due to lower mitochondrial area fraction and dysfunction in OXPHOS. These simulations indicate that a disorganized cellular ultrastructure negatively impacts metabolite transport in diabetic cardiomyopathy.This article is part of the theme issue ‘The cardiomyocyte: new revelations on the interplay between architecture and function in growth, health and disease’.

Published
2022
Full Text
View/download PDF

9. Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial

Author

Terpos, Evangelos, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Delimpasi, Sosana, additional, Beksac, Meral, additional, Katodritou, Eirini, additional, Moreau, Philippe, additional, Pompa, Alessandra, additional, Symeonidis, Argiris, additional, Bila, Jelena, additional, Oriol, Albert, additional, Mateos, Maria‐Victoria, additional, Einsele, Hermann, additional, Orfanidis, Ioannis, additional, Gries, Katharine S., additional, Fastenau, John, additional, Liu, Kevin, additional, He, Jianming, additional, Kampfenkel, Tobias, additional, Qiu, Yanping, additional, Amin, Himal, additional, Carson, Robin, additional, and Sonneveld, Pieter, additional

Published
2022
Full Text
View/download PDF

10. Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Author

Sonneveld, Pieter, primary, Terpos, Evangelos, additional, Boccadoro, Mario, additional, Delimpasi, Sosana, additional, Beksac, Meral, additional, Katodritou, Eirini, additional, Moreau, Philippe, additional, Baldini, Luca, additional, Symeonidis, Argiris, additional, Bila, Jelena, additional, Oriol, Albert, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Orfanidis, Ioannis, additional, Kampfenkel, Tobias, additional, Qiu, Yanping, additional, Amin, Himal, additional, Kosh, Michele, additional, Tran, NamPhuong, additional, Carson, Robin, additional, and Dimopoulos, Meletios A., additional

Published
2021
Full Text
View/download PDF

11. Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO

Author

Terpos, Evangelos Dimopoulos, Meletios A. Boccadoro, Mario and Delimpasi, Sosana Beksac, Meral Katodritou, Eirini Moreau, Philippe Baldini, Luca Symeonidis, Argiris Bila, Jelena and Oriol, Albert Mateos, Maria-Victoria Einsele, Hermann and Orfanidis, Ioannis Gries, Katharine S. Fastenau, John and Kampfenkel, Tobias Qiu, Yanping Amin, Himal Sonneveld, Pieter

Published
2021

12. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Author

Multiple Myeloma Research Foundation, Janssen Research and Development, Dimopoulos, Meletios A., Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M., Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, Carson, Robin, Sonneveld, Pieter, Multiple Myeloma Research Foundation, Janssen Research and Development, Dimopoulos, Meletios A., Terpos, Evangelos, Boccadoro, Mario, Delimpasi, Sosana, Beksac, Meral, Katodritou, Eirini, Moreau, Philippe, Baldini, Luca, Symeonidis, Argiris, Bila, Jelena, Oriol, Albert, Mateos, Maria Victoria, Einsele, Hermann, Orfanidis, Ioannis, Ahmadi, Tahamtan, Ukropec, Jon, Kampfenkel, Tobias, Schecter, Jordan M., Qiu, Yanping, Amin, Himal, Vermeulen, Jessica, Carson, Robin, and Sonneveld, Pieter

Abstract

Background: In a phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good partial response or better rate of 42% and was well tolerated in patients with heavily pretreated multiple myeloma. We aimed to evaluate whether daratumumab plus pomalidomide and dexamethasone would improve progression-free survival versus pomalidomide and dexamethasone alone in patients with previously treated multiple myeloma. Methods: In this ongoing, open-label, randomised, phase 3 trial (APOLLO) done at 48 academic centres and hospitals across 12 European countries, eligible patients were aged 18 years or older, had relapsed or refractory multiple myeloma with measurable disease, had an Eastern Cooperative Oncology Group performance status of 0–2, had at least one previous line of therapy, including lenalidomide and a proteasome inhibitor, had a partial response or better to one or more previous lines of antimyeloma therapy, and were refractory to lenalidomide if only one previous line of therapy was received. Patients were randomly assigned (1:1) by an interactive web-response system in a random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone. Randomisation was stratified by number of previous lines of therapy and International Staging System disease stage. All patients received oral pomalidomide (4 mg, once daily on days 1–21) and oral dexamethasone (40 mg once daily on days 1, 8, 15, and 22; 20 mg for those aged 75 years or older) at each 28-day cycle. The daratumumab plus pomalidomide and dexamethasone group received daratumumab (1800 mg subcutaneously or 16 mg/kg intravenously) weekly during cycles 1 and 2, every 2 weeks during cycles 3–6, and every 4 weeks thereafter until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was analysed in all patients who received at least one do

Published
2021

13. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, primary, Terpos, Evangelos, additional, Boccadoro, Mario, additional, Delimpasi, Sosana, additional, Beksac, Meral, additional, Katodritou, Eirini, additional, Moreau, Philippe, additional, Baldini, Luca, additional, Symeonidis, Argiris, additional, Bila, Jelena, additional, Oriol, Albert, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Orfanidis, Ioannis, additional, Ahmadi, Tahamtan, additional, Ukropec, Jon, additional, Kampfenkel, Tobias, additional, Schecter, Jordan M, additional, Qiu, Yanping, additional, Amin, Himal, additional, Vermeulen, Jessica, additional, Carson, Robin, additional, Sonneveld, Pieter, additional, Alegre Amor, Adrian, additional, Belotti, Angelo, additional, Benboubker, Lotfi, additional, Besemer, Britta, additional, Besisik, Sevgi, additional, Cavo, Michele, additional, De La Rubia Comos, Javier, additional, Dimopoulos, Meletios A., additional, Doyen, Chantal, additional, Dytfeld, Dominik, additional, Engelhardt, Monika, additional, Facon, Thierry, additional, Foà, Roberto, additional, Goldschmidt, Hartmut, additional, Grosicki, Sebastian, additional, Hajek, Roman, additional, Hayri Ozsan, Guner, additional, Hulin, Cyrille, additional, Iversen, Brian, additional, Karlin, Lionel, additional, Knop, Stefan, additional, Kyrtsonis, Marie-Christine, additional, Lahuerta, Juan Jose, additional, Leleu, Xavier, additional, Martinez Chamorro, Carmen, additional, Mateos Manteca, María-Victoria, additional, Meuleman, Nathalie, additional, Minnema, Monique, additional, Offidani, Massino, additional, Oriol Rocafiguera, Albert, additional, Pehlivan, Mustafa, additional, Pour, Ludek, additional, Roerdink, Henk Th.J., additional, Rosinol Dacsh, Laura, additional, Salwender, Hans, additional, Symeonidis, Anargyros, additional, Toftmann Hansen, Charlotte, additional, Tuglular, Tulin, additional, Unal, Ali, additional, Vlummens, Philip, additional, Vural, Filiz, additional, Wu, Ka Lung, additional, and Zweegman, Sonja, additional

Published
2021
Full Text
View/download PDF

14. Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.

Author

Terpos, Evangelos, primary, Dimopoulos, Meletios A., additional, Boccadoro, Mario, additional, Delimpasi, Sosana, additional, Beksac, Meral, additional, Katodritou, Eirini, additional, Moreau, Philippe, additional, Baldini, Luca, additional, Symeonidis, Argiris, additional, Bila, Jelena, additional, Oriol, Albert, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Orfanidis, Ioannis, additional, Gries, Katharine S., additional, Fastenau, John, additional, Kampfenkel, Tobias, additional, Qiu, Yanping, additional, Amin, Himal, additional, and Sonneveld, Pieter, additional

Published
2021
Full Text
View/download PDF

15. Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Dimopoulos, Meletios A., primary, Terpos, Evangelos, additional, Boccadoro, Mario, additional, Delimpasi, Sosana, additional, Beksac, Meral, additional, Katodritou, Eirini, additional, Moreau, Philippe, additional, Baldini, Luca, additional, Symeonidis, Argiris, additional, Bila, Jelena, additional, Oriol, Albert, additional, Mateos, Maria-Victoria, additional, Einsele, Hermann, additional, Orfanidis, Ioannis, additional, Ahmadi, Tahamtan, additional, Ukropec, Jon, additional, Kampfenkel, Tobias, additional, Schecter, Jordan, additional, Qiu, Yanping, additional, Amin, Himal, additional, Vermeulen, Jessica, additional, Carson, Robin, additional, and Sonneveld, Pieter, additional

Published
2020
Full Text
View/download PDF

17. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone +/- subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial

Author

Terpos, Evangelos Dimopoulos, Meletios A. Boccadoro, Mario and Delimpasi, Sosana Beksac, Meral Katodritou, Eirini Moreau, Philippe Pompa, Alessandra Symeonidis, Argiris Bila, Jelena and Oriol, Albert Mateos, Maria-Victoria Einsele, Hermann and Orfanidis, Ioannis Gries, Katharine S. Fastenau, John Liu, Kevin He, Jianming Kampfenkel, Tobias Qiu, Yanping Amin, Himal Carson, Robin Sonneveld, Pieter and Terpos, Evangelos Dimopoulos, Meletios A. Boccadoro, Mario and Delimpasi, Sosana Beksac, Meral Katodritou, Eirini Moreau, Philippe Pompa, Alessandra Symeonidis, Argiris Bila, Jelena and Oriol, Albert Mateos, Maria-Victoria Einsele, Hermann and Orfanidis, Ioannis Gries, Katharine S. Fastenau, John Liu, Kevin He, Jianming Kampfenkel, Tobias Qiu, Yanping Amin, Himal Carson, Robin Sonneveld, Pieter

Abstract

In the phase 3 APOLLO trial, daratumumab in combination with pomalidomide and dexamethasone (D-Pd) significantly reduced the rate of disease progression or death by 37% relative to Pd alone in patients with relapsed/refractory multiple myeloma (RRMM) who had received >= 1 prior line of therapy including lenalidomide and a proteasome inhibitor. Here, we present patient-reported outcomes (PROs) from APOLLO. Median treatment duration was 11.5 months with D-Pd and 6.6 months with Pd. PRO compliance rates were high and similar in both groups. No changes from baseline were observed for EORTC QLQ-C30 global health status scores in either group, while physical and emotional functioning, disease symptoms, and adverse effects of treatment remained at baseline levels with D-Pd but worsened with Pd. Reductions (p < 0.05) in pain and fatigue were seen at several time points with D-Pd versus Pd. Overall, these results suggest patients’ health-related quality of life remained stable when daratumumab was added to Pd, with several results favoring D-Pd versus Pd. These findings complement the significant clinical improvements observed with D-Pd and support its use in patients with RRMM.

Catalog

Books, media, physical & digital resources
See catalog results